For the 3rd quarter of the fiscal year ending March 2026, net sales were \u00a5214.986 billion (0.9% decrease YoY), operating income was \u00a54.623 billion (20.0% decrease YoY), and net income attributable to owners of parent was \u00a53.465 billion (13.1% decrease YoY).<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"2664","jir_company_name":"Kawachi Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-01-27","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/01\/2664-20260127-01.pdf","jir_short_summary":"For the 3rd quarter of the fiscal year ending March 2026, net sales were \u00a5214.986 billion (0.9% decrease YoY), operating income was \u00a54.623 billion (20.0% decrease YoY), and net income attributable to owners of parent was \u00a53.465 billion (13.1% decrease YoY).","jir_summary":"### Performance Overview\nIn the cumulative consolidated period of the 3rd quarter of the fiscal year ending March 2026, net sales amounted to \u00a5214.986 billion (0.9% decrease YoY). Operating income was \u00a54.623 billion (20.0% decrease YoY), ordinary income was \u00a55.439 billion (16.0% decrease YoY), and net income attributable to owners of parent was \u00a53.465 billion (13.1% decrease YoY), all declining from the previous year. While the domestic economy is on a moderate recovery trend, geopolitical risks and exchange rate fluctuations persist. The drugstore industry continues to face a severe environment due to intensified competition and consumer restraint caused by price increases. In response, we strengthened specialization in health foods and revised sales prices, implemented sales promotion measures such as the 65th anniversary campaign, and worked on inventory optimization.\n\n### Financial Condition and Outlook\nTotal assets were \u00a5205.095 billion (an increase of \u00a55.493 billion from the previous fiscal year-end), total liabilities were \u00a588.925 billion (an increase of \u00a53.734 billion), and total net assets were \u00a5116.169 billion (an increase of \u00a51.759 billion), resulting in an equity ratio of 56.6% (a decrease of 0.7 points). The number of stores expanded to 386 (including 159 stores with pharmacy). There is no change to the consolidated earnings forecast for the fiscal year ending March 2026, with expected net sales of \u00a5287.0 billion (0.3% decrease YoY), operating income of \u00a56.0 billion (19.6% decrease YoY), and net income attributable to owners of parent of \u00a53.7 billion (24.3% decrease YoY).","jir_financial_highlights":"Net Sales: \u00a5214,986 million (0.9% decrease YoY)\nOperating Income: \u00a54,623 million (20.0% decrease YoY)\nOrdinary Income: \u00a55,439 million (16.0% decrease YoY)\nNet Income Attributable to Owners of Parent: \u00a53,465 million (13.1% decrease YoY)\nEquity Ratio: 56.6% (0.7 points decrease YoY)\nNumber of Stores: 386 stores (including 159 stores with pharmacy) (Unknown)\nNumber of Shares Outstanding at Period-End: 24,583,420 shares (Same as previous fiscal year-end)\nNumber of Treasury Stock at Period-End: 2,249,173 shares (Same as previous fiscal year-end)","jir_category":"","jir_hashtags":"#KawachiPharmaceutical, #FinancialSummary, #JapaneseStocks","jir_key_figures":"Net Sales: \u00a5214,986 million (0.9% decrease YoY)\nOperating Income: \u00a54,623 million (20.0% decrease YoY)\nNet Income Attributable to Owners of Parent: \u00a53,465 million (13.1% decrease YoY)","jir_meta_title":"Kawachi Pharmaceutical Co., Ltd. Fiscal Year Ending March 2026 3rd Quarter Financial Results: Net Sales \u00a5214.9 Billion, Operating Income Down 20%","jir_meta_description":"Kawachi Pharmaceutical Co., Ltd.'s Fiscal Year Ending March 2026 3rd Quarter Financial Summary. Net sales of \u00a5214.986 billion (0.9% decrease YoY), operating income of \u00a54.623 billion (20.0% decrease YoY), net income of \u00a53.465 billion (13.1% decrease YoY). No revisions to earnings forecast.","jir_og_title":"Kawachi Pharmaceutical 3rd Quarter Financial Results for Fiscal Year Ending March 2026","jir_og_description":"Net sales of \u00a5214.9 billion and operating income of \u00a54.6 billion decreased YoY. Focusing on strengthening health foods and sales promotions amid a challenging market environment.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Net Sales Trend (Millions of Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"3rd Quarter FY2025\\\",\\\"3rd Quarter FY2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Sales\\\",\\\"data\\\":[216995,214986],\\\"backgroundColor\\\":\\\"#4e79a7\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Operating Income Trend (Millions of Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"3rd Quarter FY2025\\\",\\\"3rd Quarter FY2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income\\\",\\\"data\\\":[5781,4623],\\\"backgroundColor\\\":\\\"#f28e2b\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"net_profit_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Net Income Attributable to Owners of Parent Trend (Millions of Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"3rd Quarter FY2025\\\",\\\"3rd Quarter FY2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Quarterly Net Income\\\",\\\"data\\\":[3986,3465],\\\"backgroundColor\\\":\\\"#e15759\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"equity_ratio_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Equity Ratio Trend (%)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY2025 Fiscal Year-End\\\",\\\"3rd Quarter FY2026 Fiscal Year-End\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Equity Ratio\\\",\\\"data\\\":[57.3,56.6],\\\"borderColor\\\":\\\"#76b7b2\\\",\\\"fill\\\":false}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":false,\\\"min\\\":50,\\\"max\\\":60}}}}\"}, {\"jir_chart_id\": \"store_count\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Number of Stores (units)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"3rd Quarter FY2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Number of Stores\\\",\\\"data\\\":[386],\\\"backgroundColor\\\":\\\"#59a14f\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}]","ir_related_company":16960,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-21015","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n